Global Development of Anticancer Therapies for Rare Cancers, Pediatric Cancers, and Molecular Subtypes of Common Cancers

• Main Authors: H. Kim Lyerly, Jun Ren, Renzo Canetta, Gi Hyun Kim, Sumimasa Nagai, Tomohiro Yamaguchi, Ken Hatogai, Hiroshi Katayama, Silvy Da Rocha Dias, Daniel McManus, Kathy Soltys, Zhimin Yang, Olufumilayo Olopade, Nancy Goodman, Greg Reaman, Thomas Gross
• Format: Article
• Language: English
• Published: American Society of Clinical Oncology 2018-12-01
• Series: Journal of Global Oncology
• Online Access: http://ascopubs.org/doi/10.1200/JGO.18.00092

Advances in genetic sequencing and other diagnostic technologies have enabled the use of precision medicine in clinical cancer care, as well as the development of novel therapies that are targeted to specific molecular drivers of cancer. Developing these new agents and making them accessible to patients requires global clinical studies and regulatory review and approval by different national regulatory agencies. Whereas these global trials present challenges for drug developers who conduct them and regulatory agencies who oversee them, they also raise practical issues about patients with low-frequency cancers who need these therapies. A lack of uniform standards in both regulatory approval for marketing and reimbursement for approved agents across countries may make the newly developed agent either unavailable or inaccessible to patients in certain countries or regions, even if patients from those countries or regions participated in the clinical research that established the safety and efficacy of the agent. In an effort to further understand and address this need, we convened an international workshop in 2017 in North Bethesda, MD. After presentations of the individual regulatory pathways for marketing approval and reimbursement for individual nations, participants discussed expedited pathways and specific challenges for uncommon cancers. As a matter of justice, agents being developed for rare cancers, pediatric cancers, or uncommon molecular subsets of common cancers need a pragmatic, science-based regulatory policy framework to clearly specify the type and quantity of evidence needed to demonstrate efficacy from these trials and evidence to support accessibility.